Viracta Therapeutics Quote - VIRX

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

0.5822

Bid

0.5822

Offer

0.625

Volume

128,941

0.564 Day's Range 0.649

0.43 52 Week Range 1.68

Market Cap

23.563M

Previous Close

0.569

Open

0.5795

Last Trade

0.5995

Last Trade Time

Financial Volume

US$ 75,009

VWAP

0.581734

Average Volume (3m)

109,189

Shares Outstanding

39,272,434

Dividend Yield

PE Ratio

-0.46

Earnings Per Share (EPS)

-1.3

Revenue

Net Profit

-51.06M

Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein... Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. Its lead product candidate is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people who have received organ transplants. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.viracta.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

Viracta Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker VIRX. The last closing price for Viracta Therapeutics was US$0.57. Over the last year, Viracta Therapeutics shares have traded in a share price range of US$ 0.43 to US$ 1.68.

Viracta Therapeutics currently has 39,272,434 shares in issue. The market capitalisation of Viracta Therapeutics is US$23.56 million. Viracta Therapeutics has a price to earnings ratio (PE ratio) of -0.46.

Period †	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.0858	-12.8443113772	0.668	0.8201	0.5605	141125	0.62127773	CS
4	-0.1808	-23.6959370904	0.763	0.8201	0.5	124327	0.60521333	CS
12	-0.4678	-44.5523809524	1.05	1.31	0.5	109189	0.81165902	CS
26	0.1346	30.0714924039	0.4476	1.31	0.4476	108816	0.75435326	CS
52	-0.9378	-61.6973684211	1.52	1.68	0.43	115921	0.83570424	CS
156	-12.1778	-95.4373040752	12.76	12.94	0.43	174257	3.53568589	CS
260	-16.1778	-96.5262529833	16.76	18.24	0.43	193635	4.78928279	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
ME1OEMelodiol Global Health Ltd	AUD 0.006 (100.00%)	34
K2FK2fly Limited	AUD 0.1825 (82.50%)	2.49M
PRXProdigy Gold NL	AUD 0.003 (50.00%)	100.11k
ARVOCArtemis Resources Limited	AUD 0.003 (50.00%)	1.05M
MTBMount Burgess Mining Nl	AUD 0.0015 (50.00%)	5.38k
BNROBulletin Resources Limited	AUD 0.001 (-66.67%)	100k
FRSOAForrestania Resources Ltd	AUD 0.006 (-57.14%)	26k
GGEOAGrand Gulf Energy Limited	AUD 0.001 (-50.00%)	2.18M
D2OOADuxton Water Limited	AUD 0.021 (-47.50%)	4.5k
CT1Constellation Technologies Limited	AUD 0.002 (-33.33%)	50.02k
REDRed 5 Limited	AUD 0.4175 (3.09%)	135.31M
BGLBellevue Gold Limited	AUD 1.835 (-1.34%)	81.32M
NICNickel Industries Ltd	AUD 0.825 (-3.23%)	62.62M
S32South32 Limited	AUD 3.74 (1.77%)	56.22M
CXOCore Lithium Ltd	AUD 0.0855 (-6.04%)	56.06M